Patient consent to publication and data sharing in industry and NIH-funded clinical trials

被引:14
作者
Spence, O'Mareen [1 ]
Uba, Richie Onwuchekwa [2 ]
Shin, Seongbin [1 ]
Doshi, Peter [1 ]
机构
[1] Univ Maryland, Sch Pharm, Baltimore, MD 21201 USA
[2] Notre Dame Maryland Univ, Baltimore, MD USA
关键词
Informed consent; Ethics; Responsible conduct of research; Publication bias; Reporting bias; Data sharing; Clinical trials; Clinical data;
D O I
10.1186/s13063-018-2651-2
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
Background: Participants are recruited into clinical trials under the assumption that the research will contribute to medical knowledge. Therefore, non-publication trials-and, more recently, lack of data sharing-are widely considered to violate the trust of trial participants. Existing practices regarding patient consent to publication and data sharing have not been evaluated. Analyzing informed consent forms (ICFs), we studied what trial participants were told regarding investigators' intention to contribute to medical knowledge, publish trial results, and share de-identified trial data. Methods: We obtained 98 ICFs of industry-funded pre-marketing trials for all (17) antibiotics approved by the European Medicines Agency and 46 ICFs of publicly funded trials from the National Heart, Lung and Blood Institute Biologic Specimen and Data Repository Information Coordinating Center (BioLINCC) data repository. Three authors independently reviewed ICFs to identify and extract what was stated or implied regarding: (1) publication of results; (2) sharing de-identified data; (3) data ownership; (4) confidentiality of identifiable data; and (5) whether the trial will produce knowledge that offers public benefit. Consensus was obtained from the two reviewers with the greatest overall agreement on all five measures. Disagreements were resolved through discussion among all authors. Results: Four (3%) trials indicated a commitment to publish trial results; 140 (97%) did not commit to publishing trial results; six (4%) indicated a commitment to share de-identified data with third party researchers. Commitments to share were more common in publicly funded trials than industry-funded trials (7% vs 3%). A total of 103 (72%) ICFs indicated the trials will or may produce knowledge that offers public benefits, while 131 (91%) ICFs left unstated who "owned" trial data; of those with statements, the sponsor always claimed ownership. Patient confidentiality was guaranteed in 137 (95%) trials. Conclusions: Our results suggest that consent forms rarely disclose investigators' intentions regarding the sharing of de-identified data or publication of trial results.
引用
收藏
页数:5
相关论文
共 22 条
[1]   World Medical Association Declaration of Helsinki Ethical Principles for Medical Research Involving Human Subjects [J].
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2013, 310 (20) :2191-2194
[2]   UNDERREPORTING RESEARCH IS SCIENTIFIC MISCONDUCT [J].
CHALMERS, I .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1990, 263 (10) :1405-1408
[3]   Clinical trial registration - A statement from the International Committee of Medical Journal Editors [J].
DeAngelis, CD ;
Drazen, JM ;
Frizelle, FA ;
Haug, C ;
Hoey, J ;
Horton, R ;
Kotzin, S ;
Laine, C ;
Marusic, A ;
Overbeke, AJPM ;
Schroeder, TV ;
Sox, HC ;
Van der Weyden, MB .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2004, 292 (11) :1363-1364
[5]   Data too important to share: do those who control the data control the message? [J].
Doshi, Peter .
BMJ-BRITISH MEDICAL JOURNAL, 2016, 352
[6]  
ECRI Health Technology Assessment Information Services, 2002, PLYM M PA ECRI I
[7]  
Evoniuk G, 2017, BMJ-BRIT MED J, V357, pj1726
[8]   Providing Contemporary Access to Historical Biospecimen Collections: Development of the NHLBI Biologic Specimen and Data Repository Information Coordinating Center (BioLINCC) [J].
Giffen, Carol A. ;
Carroll, Leslie E. ;
Adams, John T. ;
Brennan, Sean P. ;
Coady, Sean A. ;
Wagner, Elizabeth L. .
BIOPRESERVATION AND BIOBANKING, 2015, 13 (04) :271-279
[9]  
Grady C, 2017, PLOS ONE, V12
[10]  
Institute of Medicine, 2015, SHAR CLIN TRIAL DAT